ReviewCNS drugs2023
Pharmacological Management of Borderline Personality Disorder and Common Comorbidities.
Review in CNS drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 42 citations in OpenAlex.
- Transcutaneous auricular vagus nerve stimulation and emotional responding in borderline personality disorder: a randomized single-blind, sham-controlled study.Borderline personality disorder and emotion dysregulation · 2026Article
- Documented Borderline Personality Disorder and EMR Indicators of Potential Under-Recognition in Depressive Outpatients.Medicina (Kaunas, Lithuania) · 2026Article
- Stigma and Borderline Personality Disorder: An Umbrella Scoping Review of Existing Reviews.International journal of mental health nursing · 2026Article
- Benzodiazepines at the crossroads: navigating therapeutic promise and perils of misuse.Annals of general psychiatry · 2026Review
- Correlates of Anti-Toxoplasma IgG Antibodies in Females with Borderline Personality Disorder: A Pilot Cross-Sectional Study.Neuropsychiatric disease and treatment · 2026Article
- "It seems like they are guessing": a qualitative study of the prescribing process from the perspective of individuals diagnosed with personality disorder.Frontiers in psychiatry · 2026Article
- Lithium in borderline personality disorder: neuroplasticity, anti-inflammatory action, and therapeutic potential.Frontiers in behavioral neuroscience · 2026Review
- Emoface: AI-assisted diagnostic model for differentiating major depressive disorder and bipolar disorder via facial biomarkers.Npj mental health research · 2025Article
- The Association Between Borderline Personality Disorder Symptoms and Social Behaviour Among University Students.Medicina (Kaunas, Lithuania) · 2025Article
- Wired for Intensity: The Neuropsychological Dynamics of Borderline Personality Disorders-An Integrative Review.Journal of clinical medicine · 2025Review
- Trends in pharmacological prescriptions and polypharmacy for personality disorders: a 10-year cross-sectional analysis of naturalistic data.BMC psychiatry · 2025Article
- Methylphenidate in Borderline Personality Disorder: Assessing Its Therapeutic Potential and Limitations.Life (Basel, Switzerland) · 2025Review
- Prevalence and Associated Factors of Benzodiazepine Use in Patients Attending a Community Mental Health Team in Scotland: A Cross-Sectional Survey.Clinical practice and epidemiology in mental health : CP & EMH · 2025Article
- How to Mitigate Risk in the Treatment of Patients with Borderline Personality Disorder.Current psychiatry reports · 2024Review
- Characterizing psychopharmacological prescribing practices in a large cohort of adolescents with borderline personality disorder.Borderline personality disorder and emotion dysregulation · 2024Article
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Comorbidity between borderline personality disorder (BPD) and other mental disorders is common. Although no specific pharmacological treatments have been approved for the treatment of BPD, many drugs, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), mood stabilizers, second-generation antipsychotics, and even benzodiazepines, are routinely prescribed off label. Nonetheless, recommendations for off-label drugs in these patients are highly varied, with a notable lack of agreement among clinical guidelines. The most common reason for pharmacological treatment and polypharmacy in these patients is comorbidity with other psychiatric disorders. In this context, we reviewed major clinical guidelines and the available data on pharmacotherapy in patients with BPD to develop practical recommendations to facilitate decision-making in routine clinical practice, thus helping clinicians to select the optimal therapeutic approach in patients with BPD who have comorbid disorders. This review confirmed that no clear recommendations for the pharmacological treatment are available in clinical guidelines. Therefore, based on the available evidence, we have developed a series of recommendations for pharmacotherapy in patients with BPD who present the four most common comorbidities (affective, anxiety, eating, and drug use disorders). Here, we discuss the recommended treatment approach for each of these comorbid disorders. The prescription of medications should be considered only as an adjunct to BPD-specific psychotherapy. Polypharmacy and the use of unsafe drugs (i.e., with a risk of overdose) should be avoided. Our review highlights the need for more research to provide more definitive guidance and to develop treatment algorithms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.